Biblio

Author Title Type [ Year(Asc)]
Filters: First Letter Of Title is C and Author is Huang, He  [Clear All Filters]
2024
Hwang WYk, Takahashi S, Choi B, Huang H, Kawamata S, Ng SChin, Gupta P, Hamidieh AAli, Koaykul C, Irawan C, et al. Challenges in Global Access to CAR-T cells: an Asian Perspective. Blood Cell Ther. 2024;7(1):10-13.
Zhu M, Han Y, Gu T, Wang R, Si X, Kong D, Zhao P, Wang X, Li J, Zhai X, et al. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. Cell Rep. 2024;43(4):114065.
Guan F, Yang L, Chen Y, Shi J, Song X, Lai X, Lu Y, Liu L, Ouyang G, Zhao Y, et al. Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study. Cancer. 2024.
Wang L, Lv Y, Zhou L, Wu S, Zhu Y, Fu S, Ding S, Hong R, Zhang M, Yu H, et al. Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies. Exp Hematol Oncol. 2024;13(1):28.
2023
Yang T, Jiang B, Luo Y, Zhao Y, Ouyang G, Yu J, Lan J, Lu Y, Lai X, Ye B, et al. Comparison of the prognostic predictive value of Molecular International Prognostic Scoring System and Revised International Prognostic Scoring System in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms. Am J Hematol. 2023.
Zheng H, Chen Y, Luo Q, Zhang J, Huang M, Xu Y, Huo D, Shan W, Tie R, Zhang M, et al. Correction: Generating hematopoietic cells from human pluripotent stem cells: approaches, progress and challenges. Cell Regen. 2023;12(1):32.
2022
Yan M, Su F, Cheng F, Shi J, Zheng W, Luo Y, Wang J, Lu H, Zhou H, Huang H, et al. Chronic graft-versus-host disease-related polymyositis and myocarditis: A case report and review of the literature. Transpl Immunol. 2022:101598.
Wang L, Hong R, Zhou L, Wang Y, Lv Y, Ni F, Zhang M, Zhao H, Ding S, Chang AH, et al. Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy. Cytotherapy. 2022.
2021
Wu K, Wang L-M, Liu M, Xiu Y, Hu Y, Fu S, Huang H, Xu B, Xiao H. The CD226-ERK1/2-LAMP1 pathway is an important mechanism for Vγ9Vδ2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells. Cancer Sci. 2021.
2020
Zhao Y, Shi J, Luo Y, Gao F, Tan Y, Lai X, Yu J, Wei G, Huang H. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020.
Mohty M, Duléry R, Gauthier J, Malard F, Brissot E, Aljurf M, Bazarbachi A, Chabanon C, Kharfan-Dabaja MA, Savani BN, et al. CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplant. 2020.
2019
Yan C-H, Liu Q-F, Wu D-P, Zhang X, Xu L-P, Zhang X-H, Wang Y, Huang H, Bai H, Huang F, et al. Corrigendum to 'Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus host disease guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractor. Biol Blood Marrow Transplant. 2019.